First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. (Q39105350)
Jump to navigation
Jump to search
scientific article published on 23 January 2017
Language | Label | Description | Also known as |
---|---|---|---|
English | First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. |
scientific article published on 23 January 2017 |
Statements
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study (English)
Daniel S W Tan
Rita Chiari
Luis Paz-Ares
Juergen Wolf
Sarayut L Geater
Maximillian Hochmair
Chun-Ming Tsai
Rosario G Campelo
Tracey McCulloch
Paramita Sen
Margaret Dugan
Serafino Pantano
Fabrice Branle
Cristian Massacesi
Jean-Charles Soria